|Bid||5.63 x 1800|
|Ask||5.93 x 2200|
|Day's range||5.57 - 6.10|
|52-week range||3.86 - 11.57|
|Beta (5Y monthly)||1.44|
|PE ratio (TTM)||N/A|
|Earnings date||23 Feb 2022 - 28 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||18.17|
With me on today's call are president and chief executive officer, Mike Sherman; chief financial and business officer, Mike Andriole; Allen Melemed, our chief medical officer; and Josh Allen, our chief technology officer of Imipridones. Before we begin, I would like to remind you that the statements made on today's call include forward-looking statements within the meaning of the Private Litigation Reform Act of 1995 and are subject to risks and uncertainties, and other factors.
Chimerix (CMRX) delivered earnings and revenue surprises of 0.00% and -72.56%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Chimerix (CMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.